For­mer No­vo chair­man Göran An­do joins the board as Tes­sa bags $50M in ad­di­tion­al fund­ing

As Tes­sa Ther­a­peu­tics preps a piv­otal late-stage tri­al read­out and ramps up clin­i­cal ac­tiv­i­ty for ear­ly-stage as­sets, it will be joined by a high pro­file board mem­ber as well as new in­vestors who just in­fused $50 mil­lion in­to the com­pa­ny.

Göran An­do, the re­cent chair­man of No­vo Nordisk, is now an in­de­pen­dent di­rec­tor at Tes­sa. He joins a team that now has a whop­ping to­tal of $130 mil­lion to steer its virus-spe­cif­ic T cell tech­nol­o­gy-based prod­ucts to the mar­ket, in­clud­ing an $80 mil­lion raise from a sig­nif­i­cant group of Asian in­vestors an­nounced four months ago. Lead­ing that well-heeled pack was Temasek, the sov­er­eign wealth fund of Sin­ga­pore, where Tes­sa is based.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER